Drug intelligence / Profile preview

GRK006

Development stage: Preclinical
Lead developer: Suzhou Glanke Medical Technology
Modality: Small Molecules
Administration: Intravenous

Overview

GRK006 is an investigational small molecule therapeutic candidate being developed by Suzhou Glanke Medical Technology (GrandKol) for the treatment of traumatic brain injury (TBI). The drug is designed to block a specific cell death channel that is activated following brain trauma, thereby protecting neurons from injury-induced cell death. GRK006 is intended for intravenous (IV) administration during the acute phase of brain injury, with potential applications in treating injuries resulting from motor vehicle accidents, sports-related impacts, falls, and battlefield blast-induced trauma.

Targets

TRPM4 (Calcium-activated non-selective cation channel TRPM4)

Beyond the preview

Go deeper on GRK006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GRK006.

Explore the full profile